{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T07:18:48Z","timestamp":1781939928540,"version":"3.54.5"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,19]]},"DOI":"10.7759\/cureus.30466","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T11:44:47Z","timestamp":1666179887000},"source":"Crossref","is-referenced-by-count":6,"title":["Sugammadex to Facilitate Neurologic Assessment in Severely Brain-Injured Patients: Retrospective Analysis and Practical Guidance"],"prefix":"10.7759","author":[{"given":"Sara J","family":"Hyland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Punit A","family":"Pandya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron J","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C","family":"Yehsakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.accpm.2020.01.005","article-title":"Guidelines on muscle relaxants and reversal in anaesthesia","volume":"39","author":"Plaud B","year":"2020","unstructured":"Plaud B, Baillard C, Bourgain JL, et al.. Guidelines on muscle relaxants and reversal in anaesthesia. Anaesth Crit Care Pain Med. 2020, 39:125-42. 10.1016\/j.accpm.2020.01.005","journal-title":"Anaesth Crit Care Pain Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0000000000001409","article-title":"Current status of neuromuscular reversal and monitoring: challenges and opportunities","volume":"126","author":"Brull SJ","year":"2017","unstructured":"Brull SJ, Kopman AF. Current status of neuromuscular reversal and monitoring: challenges and opportunities. Anesthesiology. 2017, 126:173-90. 10.1097\/ALN.0000000000001409","journal-title":"Anesthesiology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0604-1","article-title":"Sugammadex: A review of neuromuscular blockade reversal","volume":"76","author":"Keating GM","year":"2016","unstructured":"Keating GM. Sugammadex: A review of neuromuscular blockade reversal. Drugs. 2016, 76:1041-52. 10.1007\/s40265-016-0604-1","journal-title":"Drugs"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/anae.13738","article-title":"Conceptual and technical insights into the basis of neuromuscular monitoring","volume":"72 Suppl 1","author":"Naguib M","year":"2017","unstructured":"Naguib M, Brull SJ, Johnson KB. Conceptual and technical insights into the basis of neuromuscular monitoring. Anaesthesia. 2017, 72 Suppl 1:16-37. 10.1111\/anae.13738","journal-title":"Anaesthesia"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-019-05805-9","article-title":"A management algorithm for patients with intracranial pressure monitoring: the Seattle International Severe Traumatic Brain Injury Consensus Conference (SIBICC)","volume":"45","author":"Hawryluk GW","year":"2019","unstructured":"Hawryluk GW, Aguilera S, Buki A, et al.. A management algorithm for patients with intracranial pressure monitoring: the Seattle International Severe Traumatic Brain Injury Consensus Conference (SIBICC). Intensive Care Med. 2019, 45:1783-94. 10.1007\/s00134-019-05805-9","journal-title":"Intensive Care Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7705\/biomedica.4786","article-title":"The delayed detection of an acute neurological worsening increases traumatic brain injury lethality","volume":"40","author":"Rodr\u00edguez A","year":"2020","unstructured":"Rodr\u00edguez A, Cervera E, Tuesca R, Fl\u00f3rez K, Romero R, Villalba PJ. The delayed detection of an acute neurological worsening increases traumatic brain injury lethality. Biomedica. 2020, 40:89-101. 10.7705\/biomedica.4786","journal-title":"Biomedica"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jen.2018.05.019","article-title":"Ultra-rapid reversal of rocuronium-induced paralysis with sugammadex in the emergency department","volume":"44","author":"Smack MA","year":"2018","unstructured":"Smack MA, Moore M, Hong C, Gravino D. Ultra-rapid reversal of rocuronium-induced paralysis with sugammadex in the emergency department. J Emerg Nurs. 2018, 44:529-31. 10.1016\/j.jen.2018.05.019","journal-title":"J Emerg Nurs"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-019-00901-6","article-title":"Sugammadex administration to facilitate timely neurologic examination in the traumatic brain injury patient","volume":"32","author":"Curley JM","year":"2020","unstructured":"Curley JM, Ciceri DP, Culp WC Jr. Sugammadex administration to facilitate timely neurologic examination in the traumatic brain injury patient. Neurocrit Care. 2020, 32:880-2. 10.1007\/s12028-019-00901-6","journal-title":"Neurocrit Care"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2021.03.001","article-title":"Sugammadex to reverse neuromuscular blockade prior to withdrawal of life support","volume":"62","author":"Lemus R","year":"2021","unstructured":"Lemus R, Guider W, Gee SW, Humphrey L, Tobias JD. Sugammadex to reverse neuromuscular blockade prior to withdrawal of life support. J Pain Symptom Manage. 2021, 62:438-42. 10.1016\/j.jpainsymman.2021.03.001","journal-title":"J Pain Symptom Manage"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/08971900211048747","article-title":"Rocuronium reversal in the emergency department: Retrospective evaluation of hemodynamic instability following administration of sugammadex versus neostigmine with glycopyrrolate","author":"Hile GB","year":"2021","unstructured":"Hile GB, Healy KJ, Almassalkhi LR. Rocuronium reversal in the emergency department: Retrospective evaluation of hemodynamic instability following administration of sugammadex versus neostigmine with glycopyrrolate. J Pharm Pract. 2021, 8971900211048747. 10.1177\/08971900211048747","journal-title":"J Pharm Pract"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/PEC.0000000000002126","article-title":"Sugammadex: A limited but important role in emergency medicine","volume":"36","author":"Chen B","year":"2020","unstructured":"Chen B. Sugammadex: A limited but important role in emergency medicine. Pediatr Emerg Care. 2020, 36:296-301. 10.1097\/PEC.0000000000002126","journal-title":"Pediatr Emerg Care"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2020.08.006","article-title":"What is the role of sugammadex in the emergency department?","volume":"60","author":"Lentz S","year":"2021","unstructured":"Lentz S, Morrissette KM, Porter BA, DeWitt KM, Koyfman A, Long B. What is the role of sugammadex in the emergency department?. J Emerg Med. 2021, 60:44-53. 10.1016\/j.jemermed.2020.08.006","journal-title":"J Emerg Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2019.1649393","article-title":"Safety of sugammadex for reversal of neuromuscular block","volume":"18","author":"Honing G","year":"2019","unstructured":"Honing G, Martini CH, Bom A, et al.. Safety of sugammadex for reversal of neuromuscular block. Expert Opin Drug Saf. 2019, 18:883-91. 10.1080\/14740338.2019.1649393","journal-title":"Expert Opin Drug Saf"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000000092","article-title":"Sugammadex: A scientific review including safety and efficacy, update on regulatory issues, and clinical use in Europe","volume":"22","author":"Jahr JS","year":"2015","unstructured":"Jahr JS, Miller JE, Hiruma J, Emaus K, You M, Meistelman C. Sugammadex: A scientific review including safety and efficacy, update on regulatory issues, and clinical use in Europe. Am J Ther. 2015, 22:288-97. 10.1097\/MJT.0000000000000092","journal-title":"Am J Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000026796","article-title":"Sugammadex induced bradycardia and hypotension: a case report and literature review","volume":"100","author":"Teng IC","year":"2021","unstructured":"Teng IC, Chang YJ, Lin YT, Chu CC, Chen JY, Wu ZF. Sugammadex induced bradycardia and hypotension: a case report and literature review. Medicine (Baltimore). 2021, 100:e26796. 10.1097\/MD.0000000000026796","journal-title":"Medicine (Baltimore)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.4103\/joacp.JOACP_132_20","article-title":"Cardiovascular adverse effects of sugammadex","volume":"36","author":"Kapoor MC","year":"2020","unstructured":"Kapoor MC. Cardiovascular adverse effects of sugammadex. J Anaesthesiol Clin Pharmacol. 2020, 36:469-70. 10.4103\/joacp.JOACP_132_20","journal-title":"J Anaesthesiol Clin Pharmacol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8767195","article-title":"Sugammadex-associated hypotension, bradycardia, asystole, and death","volume":"2020","author":"Mirza K","year":"2020","unstructured":"Mirza K, Landoski K, Thakar D, Heir-Singh J, Jackson T, Kassab C. Sugammadex-associated hypotension, bradycardia, asystole, and death. Case Rep Anesthesiol. 2020, 2020:8767195. 10.1155\/2020\/8767195","journal-title":"Case Rep Anesthesiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2018.03.003","article-title":"Sugammadex-induced bradycardia and asystole: how great is the risk?","volume":"121","author":"Hunter JM","year":"2018","unstructured":"Hunter JM, Naguib M. Sugammadex-induced bradycardia and asystole: how great is the risk?. Br J Anaesth. 2018, 121:8-12. 10.1016\/j.bja.2018.03.003","journal-title":"Br J Anaesth"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of observational studies in Epidemiology (Strobe) statement: Guidelines for reporting observational studies","volume":"370","author":"von Elm E","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, et al.. The strengthening the reporting of observational studies in Epidemiology (Strobe) statement: Guidelines for reporting observational studies. Lancet. 2007, 370:1453-7. 10.1016\/S0140-6736(07)61602-X","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1345\/aph.19381","article-title":"The origin of the \"ideal\" body weight equations","volume":"34","author":"Pai MP","year":"2000","unstructured":"Pai MP, Paloucek FP. The origin of the \"ideal\" body weight equations. Ann Pharmacother. 2000, 34:1066-9. 10.1345\/aph.19381","journal-title":"Ann Pharmacother"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/anae.14160","article-title":"The comparative efficacy and safety of sugammadex and neostigmine in reversing neuromuscular blockade in adults. A Cochrane systematic review with meta-analysis and trial sequential analysis","volume":"73","author":"Hristovska AM","year":"2018","unstructured":"Hristovska AM, Duch P, Allingstrup M, Afshari A. The comparative efficacy and safety of sugammadex and neostigmine in reversing neuromuscular blockade in adults. A Cochrane systematic review with meta-analysis and trial sequential analysis. Anaesthesia. 2018, 73:631-41. 10.1111\/anae.14160","journal-title":"Anaesthesia"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0000000000003256","article-title":"Sugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications (stronger): a multicenter matched cohort analysis","volume":"132","author":"Kheterpal S","year":"2020","unstructured":"Kheterpal S, Vaughn MT, Dubovoy TZ, et al.. Sugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications (stronger): a multicenter matched cohort analysis. Anesthesiology. 2020, 132:1371-81. 10.1097\/ALN.0000000000003256","journal-title":"Anesthesiology"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.21037\/jeccm.2017.09.03","article-title":"Surgical interventions for severe traumatic brain injury","volume":"1","author":"Fong R","year":"2017","unstructured":"Fong R, Konakondla S, Schirmer CM, Lacroix M. Surgical interventions for severe traumatic brain injury. J Emerg Crit Care Med. 2017, 1:28. 10.21037\/jeccm.2017.09.03","journal-title":"J Emerg Crit Care Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39461.643438.25","article-title":"Predicting outcome after traumatic brain injury: practical prognostic models based on large cohort of international patients","volume":"336","author":"Perel P","year":"2008","unstructured":"Perel P, Arango M, Clayton T, et al.. Predicting outcome after traumatic brain injury: practical prognostic models based on large cohort of international patients. BMJ. 2008, 336:425-9. 10.1136\/bmj.39461.643438.25","journal-title":"BMJ"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e318225764e","article-title":"Delayed neurological recovery after decompressive craniectomy for severe nonpenetrating traumatic brain injury","volume":"39","author":"Ho KM","year":"2011","unstructured":"Ho KM, Honeybul S, Litton E. Delayed neurological recovery after decompressive craniectomy for severe nonpenetrating traumatic brain injury. Crit Care Med. 2011, 39:2495-500. 10.1097\/CCM.0b013e318225764e","journal-title":"Crit Care Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3171\/2020.7.FOCUS20439","article-title":"Morbidity and mortality in elderly patients undergoing evacuation of acute traumatic subdural hematoma","volume":"49","author":"Kerezoudis P","year":"2020","unstructured":"Kerezoudis P, Goyal A, Puffer RC, Parney IF, Meyer FB, Bydon M. Morbidity and mortality in elderly patients undergoing evacuation of acute traumatic subdural hematoma. Neurosurg Focus. 2020, 49:E22. 10.3171\/2020.7.FOCUS20439","journal-title":"Neurosurg Focus"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-017-0451-2","article-title":"Emergency neurological life support: airway, ventilation, and sedation","volume":"27","author":"Rajajee V","year":"2017","unstructured":"Rajajee V, Riggs B, Seder DB. Emergency neurological life support: airway, ventilation, and sedation. Neurocrit Care. 2017, 27:4-28. 10.1007\/s12028-017-0451-2","journal-title":"Neurocrit Care"},{"key":"ref28","unstructured":"Hospira, Inc.. Rocuronium bromide (package insert). (2019). Accessed: May 27, 2022: http:\/\/labeling.pfizer.com\/ShowLabeling.aspx."},{"key":"ref29","article-title":"Chapter 13: pharmacology of muscle relaxants and their antagonists","author":"Naguib M","year":"2004","unstructured":"Naguib M, Lien CA. Chapter 13: pharmacology of muscle relaxants and their antagonists. Miller\u2019s Anesthesia, 6th ed. Miller RD (ed): Elsevier Churchill Livingstone, Philadelphia, PA; 2004. 1:1-175."},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-200305000-00004","article-title":"Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action","volume":"98","author":"Debaene B","year":"2003","unstructured":"Debaene B, Plaud B, Dilly MP, Donati F. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology. 2003, 98:1042-8. 10.1097\/00000542-200305000-00004","journal-title":"Anesthesiology"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000002670","article-title":"Consensus statement on perioperative use of neuromuscular monitoring","volume":"127","author":"Naguib M","year":"2018","unstructured":"Naguib M, Brull SJ, Kopman AF, et al.. Consensus statement on perioperative use of neuromuscular monitoring. Anesth Analg. 2018, 127:71-80. 10.1213\/ANE.0000000000002670","journal-title":"Anesth Analg"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1227\/NEU.0000000000001432","article-title":"Guidelines for the management of severe traumatic brain injury, fourth edition","volume":"80","author":"Carney N","year":"2017","unstructured":"Carney N, Totten AM, O'Reilly C, et al.. Guidelines for the management of severe traumatic brain injury, fourth edition. Neurosurgery. 2017, 80:6-15. 10.1227\/NEU.0000000000001432","journal-title":"Neurosurgery"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.4103\/joacp.JOACP_346_19","article-title":"Decrease in heart rate following the administration of sugammadex in adults","volume":"36","author":"Sims T","year":"2020","unstructured":"Sims T, Peterson J, Hakim M, Roth C, Tumin D, Tobias JD, Hansen JK. Decrease in heart rate following the administration of sugammadex in adults. J Anaesthesiol Clin Pharmacol. 2020, 36:465-9. 10.4103\/joacp.JOACP_346_19","journal-title":"J Anaesthesiol Clin Pharmacol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00081","article-title":"Identification and management of paroxysmal sympathetic hyperactivity after traumatic brain injury","volume":"11","author":"Zheng RZ","year":"2020","unstructured":"Zheng RZ, Lei ZQ, Yang RZ, Huang GH, Zhang GM. Identification and management of paroxysmal sympathetic hyperactivity after traumatic brain injury. Front Neurol. 2020, 11:81. 10.3389\/fneur.2020.00081","journal-title":"Front Neurol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1093\/bjaceaccp\/mkr058","article-title":"Cardiovascular complications of brain injury","volume":"12","author":"Gregory T","year":"2012","unstructured":"Gregory T, Smith M. Cardiovascular complications of brain injury. Contin Educ Anaesth Crit Care Pain. 2012, 12:67-71. 10.1093\/bjaceaccp\/mkr058","journal-title":"Contin Educ Anaesth Crit Care Pain"},{"key":"ref36","unstructured":"Merck & Co, Inc.. BRIDION\u00ae (sugammadex) (package insert). (2021). Accessed: February 12, 2022: https:\/\/www.merckconnect.com\/bridion\/dosing-administration\/."},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.5414\/CP202145","article-title":"Effects of sugammadex on coagulation: it does not represent a bleeding risk in surgical patients","volume":"52","author":"Carron M","year":"2014","unstructured":"Carron M. Effects of sugammadex on coagulation: it does not represent a bleeding risk in surgical patients. Int J Clin Pharmacol Ther. 2014, 52:824. 10.5414\/CP202145","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-68164-2","article-title":"Assessment of the effects of sugammadex on coagulation profiles using thromboelastographic parameters","volume":"10","author":"Kang WS","year":"2020","unstructured":"Kang WS, Lim H, Kim BS, Lee Y, Hahm KD, Kim SH. Assessment of the effects of sugammadex on coagulation profiles using thromboelastographic parameters. Sci Rep. 2020, 10:11179. 10.1038\/s41598-020-68164-2","journal-title":"Sci Rep"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aev437","article-title":"Sugammadex and neostigmine dose-finding study for reversal of residual neuromuscular block at a train-of-four ratio of 0.2 (SUNDRO20)\u2020","volume":"116","author":"Kaufhold N","year":"2016","unstructured":"Kaufhold N, Schaller SJ, St\u00e4uble CG, Baum\u00fcller E, Ulm K, Blobner M, Fink H. Sugammadex and neostigmine dose-finding study for reversal of residual neuromuscular block at a train-of-four ratio of 0.2 (SUNDRO20)\u2020. Br J Anaesth. 2016, 116:233-40. 10.1093\/bja\/aev437","journal-title":"Br J Anaesth"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e3181f4182a","article-title":"Sugammadex and neostigmine dose-finding study for reversal of shallow residual neuromuscular block","volume":"113","author":"Schaller SJ","year":"2010","unstructured":"Schaller SJ, Fink H, Ulm K, Blobner M. Sugammadex and neostigmine dose-finding study for reversal of shallow residual neuromuscular block. Anesthesiology. 2010, 113:1054-60. 10.1097\/ALN.0b013e3181f4182a","journal-title":"Anesthesiology"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1213\/01.ane.0000260135.46070.c3","article-title":"A randomized, dose-finding, phase II study of the selective relaxant binding drug, Sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block","volume":"104","author":"Groudine SB","year":"2007","unstructured":"Groudine SB, Soto R, Lien C, Drover D, Roberts K. A randomized, dose-finding, phase II study of the selective relaxant binding drug, Sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block. Anesth Analg. 2007, 104:555-62. 10.1213\/01.ane.0000260135.46070.c3","journal-title":"Anesth Analg"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1177\/0300060520985679","article-title":"Efficacy and safety of sugammadex doses calculated on the basis of corrected body weight and total body weight for the reversal of deep neuromuscular blockade in morbidly obese patients","volume":"49","author":"Li D","year":"2021","unstructured":"Li D, Wang Y, Zhou Y, Yin C. Efficacy and safety of sugammadex doses calculated on the basis of corrected body weight and total body weight for the reversal of deep neuromuscular blockade in morbidly obese patients. J Int Med Res. 2021, 49:300060520985679. 10.1177\/0300060520985679","journal-title":"J Int Med Res"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1111\/anae.13344","article-title":"Appropriate dosing of sugammadex to reverse deep rocuronium-induced neuromuscular blockade in morbidly obese patients","volume":"71","author":"Loupec T","year":"2016","unstructured":"Loupec T, Frasca D, Rousseau N, Faure JP, Mimoz O, Debaene B. Appropriate dosing of sugammadex to reverse deep rocuronium-induced neuromuscular blockade in morbidly obese patients. Anaesthesia. 2016, 71:265-72. 10.1111\/anae.13344","journal-title":"Anaesthesia"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2044.2011.06782.x","article-title":"Ideal versus corrected body weight for dosage of sugammadex in morbidly obese patients","volume":"66","author":"Van Lancker P","year":"2011","unstructured":"Van Lancker P, Dillemans B, Bogaert T, Mulier JP, De Kock M, Haspeslagh M. Ideal versus corrected body weight for dosage of sugammadex in morbidly obese patients. Anaesthesia. 2011, 66:721-5. 10.1111\/j.1365-2044.2011.06782.x","journal-title":"Anaesthesia"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1186\/s12871-017-0429-9","article-title":"Preparing for the unexpected: special considerations and complications after sugammadex administration","volume":"17","author":"Iwasaki H","year":"2017","unstructured":"Iwasaki H, Renew JR, Kunisawa T, Brull SJ. Preparing for the unexpected: special considerations and complications after sugammadex administration. BMC Anesthesiol. 2017, 17:140. 10.1186\/s12871-017-0429-9","journal-title":"BMC Anesthesiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/113935-sugammadex-to-facilitate-neurologic-assessment-in-severely-brain-injured-patients-retrospective-analysis-and-practical-guidance","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:51:51Z","timestamp":1707508311000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/113935-sugammadex-to-facilitate-neurologic-assessment-in-severely-brain-injured-patients-retrospective-analysis-and-practical-guidance"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,19]]},"references-count":45,"URL":"https:\/\/doi.org\/10.7759\/cureus.30466","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,19]]}}}